Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial.
Sophie GottschalkShinwan KanyHans-Helmut KönigHarry J G M CrijnsPanos E VardasA John CammKarl WegscheiderAndreas MetznerAndreas RilligPaulus F KirchhofJudith DamsPublished in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)
From a German healthcare payer's perspective, health benefits of ERC may come at reasonable costs as indicated by the ICER point estimates. Taking statistical uncertainty into account, cost-effectiveness of ERC is highly probable at a willingness-to-pay value of ≥€55 000 per additional life year or year without a primary outcome. Future studies examining the cost-effectiveness of ERC in other countries, subgroups with higher benefit from rhythm control therapy, or cost-effectiveness of different modes of ERC are warranted.
Keyphrases
- healthcare
- atrial fibrillation
- palliative care
- public health
- heart failure
- heart rate
- quality improvement
- mental health
- pain management
- machine learning
- big data
- randomized controlled trial
- affordable care act
- left atrial
- phase iii
- bone marrow
- acute coronary syndrome
- catheter ablation
- health information
- health insurance
- phase ii
- open label
- risk assessment
- placebo controlled
- artificial intelligence
- climate change